In 1982 Viberti et al
1 first showed that increased levin patients with hypertension. For example, increased UAER in poorly controlled hypertensive els of urine albumin excretion, even with the 'normal' proteinuric range, heralds the onset of renal patients was first noted by Parving et al 8 in 1974 . Since then there has been great research enthusiasm impairment in patients with insulin dependent diabetes mellitus (IDDM). Since the 1980s, measurein this area, with several studies showing correment of microalbuminuria (MAL) has been conlations of UAE with left ventricular mass, [9] [10] [11] lipsidered to be an important advance in diabetes ids, 11 upper half body obesity, 12 insulin levels durmanagement, especially since MAL in insulin ing oral glucose tolerance test, 12,13 target organ dependent-and non-insulin dependent-diabetes damage manifestations such as hypertensive retinal mellitus (NIDDM) patients appears to be closely changes, 9, 14 and the extension of atherosclerotic disassociated with cardiovascular and renal compliease in carotid arteries. 15 MAL may be more prevacations. lent in salt-sensitive hypertensives 16 and in 'nonParallel to the recognition of the importance of dippers' detected following 24-h ambulatory BP MAL in diabetics, further research focussed on carmonitoring. 17 These 'non-dippers' are considered to diovascular disease, especially hypertension, and have a higher BP 'load' and have been shown to the significance or value of measuring MAL in the have greater target organ damage. general population setting.
In a study of 333 treated hypertensive men, target The early reports by Yudkin et al 2 and Damsgaard organ damage, which was defined as history of caret al 3 in non-diabetics and in elderly subjects from diovascular event(s) and/or major electrocardiothe general (unselected) population found an graphic changes, was more common in the microalincreased risk of atherosclerotic arterial disease and buminuric group (n = 284) when compared to a a reduced survival in microalbuminurics when comnormoalbuminuric group (n = 249) (47.6% vs 30.9%, pared to normoalbuminurics. Several large popurespectively). 12 Rather unexpectedly, however, the lation studies, such as the Mexico City Diabetes presence of MAL failed to predict future cardioStudy, 4 and others from New Zealand, 5 Finland 6 and vascular morbidity or mortality, since in a followBritain 7 have reported a correlation of urine albumin up of 3.3 years of the whole study population no excretion rate (UAER) with several established carexcess was noted in the microalbuminuric group.
18 diovascular risk factors, including blood pressure In a small group of 12 hypertensive patients with (BP), body mass index, smoking, lipids, hyperinsuliinitially overt proteinuria (Ͼ100 mg/24 h), an naemia, and the male sex. In the Finnish study, increased prevalence of cardiovascular complithere was also an association with increased coroncations was noted, suggesting that only the presence ary morbidity and mortality. 6 Nevertheless, the of macroalbuminuria, rather than MAL, had progprevalence of MAL in the general population was nostic value in hypertensives. 18 However, the HARlow and as the significance of reduction of UAER VEST study found no correlation of UAER and left by medical interventions remained unclear, routine ventricular mass in 870 relatively young (18 to 45-measurement of MAL in the general population year-old) hypertensives, 19 which is in contrast to seems unrewarding.
general population studies. 6 However, targeting high risk patient groups may Two recent cross-sectional studies with large be of greater value. If MAL represented vascular numbers of enrolled patients have further addressed damage and had prognostic implications, hypertenthe controversy on the role of MAL as a cardiovascusive target organ damage may thus be more common lar risk factor in hypertension. 20 suggesting increased microvascular permeability probably secondary to group was 31%, 24%, 6% and 7% which was significantly higher compared to corresponding values inflammatory mediators such as the cytokines. 24 However, MAL may also be considered to reflect in the normoalbuminuric group (22%, 14%, 4% and 5%, respectively; P Ͻ 0.0001). local renal dysfunction characterised by increased intraglomerular pressure and filtration fraction, In this issue of the Journal of Human Hypertension, we report a study by Jensen et al 21 of 1254 leading to increased transglomerular membrane albumin passage and subsequently nephrosclerosis. hypertensive subjects from the Copenhagen City Heart Study. Whilst no difference in the prevalence In this respect, MAL would be a predictor of future decline in glomerular filtration rate. Although this of cardiovascular disease between the normoalbuminuric and microalbuminuric groups was found, has been proved in the case of diabetes, no similar data are yet available in hypertensive patients. UAER (when analysed as a continuous variable) was significantly associated with cardiovascular disease Following the accumulation of knowledge on the clinical significance of MAL, many questions arise. in the whole study population (odds ratio 1.32). However, only 59 patients were included in the For example, is MAL worth measuring routinely? If present, is it worth treating it? If so, which are the microalbuminuric group, with only five (7%) of them having positive history of cardiovascular disdrugs of first choice, and why? However, in diabetes, many of the answers appear ease and/or electrocardiographic changes -in view of the small numbers, the lack of a significant associto be there; for example, many diabetologists would probably say that 'yes, microalbuminuria is worth ation between cardiovascular disease and normoalbuminuric/MAL categories is unsurprising.
measuring and treating with ACE inhibitors'. In hypertension, however, the easy answers elude us. In addition, if patients with white-coat hypertension, who accounted for a significant portion of the First of all, from the existing studies in hypertension, no definitive data are available on the whole population (as stated by the authors) were excluded from the analysis, the association between additional cardiovascular and/or renal risks that MAL imposes on these patients. 25 Secondly, the UAER and cardiovascular disease would become much weaker, since white-coat hypertensives have a exact risk of a subject with essential hypertension and normal renal function, either with or without lower prevalence of MAL compared to patients with established hypertension.
MAL, for developing renal failure is not known. Indeed, the hypothesis that mild to moderate hyperHowever, there is no consensus on the definition of MAL in arterial hypertension and perhaps we do tension causes end stage renal failure has not been adequately tested and there is a viewpoint that nonneed one. As Jensen et al 21 point out, most studies in hypertensive subjects have used the definition of malignant essential hypertension does not actually damage the kidneys. 26, 27 Thirdly, long-term prospec-MAL applied to diabetic subjects, that is 15-150 g/min in overnight collections of 20-tive longitudinal studies, lasting longer than 1 year, of reversing MAL using several antihypertensive 200 g/min in 24-h collections. There is also the recurring problem of a reliable assay, inter-and drugs, with principal end-points of cardiovascular and renal protection, have not so far been conducintra-assay variability and reproducibility. Whilst the study of Jensen et al 21 found MAL indepented.
In conclusion, MAL could perhaps be used to disdently related to the more frequent use of calcium channel blockers, more information on the role of cern between hypertensives who are prone to develop cardiovascular/renal complications and antihypertensive therapy on MAL is needed, especially since 20% of the study population was those who are not. 24 However, whilst awaiting results from studies on the long term significance of on antihypertensive therapy. Indeed, many antihypertensive drugs do exert a lowering effect on UAER MAL and efficacy of specific treatments, it still seems rather premature to recommend widespread (although not normalising it). When one considers the specific action of the angiotensin-converting routine measuring of UAER in clinical practice today. For the present, UAER measurement should enzyme (ACE) inhibitors on glomerular haemodynamics, with reduction of intraglomerular pressure still remain a research tool in hypertension. through selective dilatation of efferent arterioles, a more beneficial effect on lowering UAER would be References expected with this particular class of antihyperten-
